Henri Beaufour is a French businessman, the billionaire heir and a major controlling shareholder of Ipsen (Euronext: IPN), a global biopharmaceutical company specializing in Oncology, Rare Disease, and Neuroscience. His fortune is generational, rooted in the company founded by his grandfather, Dr. Henri Beaufour, in 1929 (as Beaufour Laboratories).

Henri's education is elite: he holds a bachelor's of arts from Georgetown University in Washington, D.C.. He and his sister, Anne Beaufour, control a substantial 57 percent of Ipsen's shares and a disproportionate 73 percent of its voting rights (via the holding company Beech Tree), ensuring the family's command over the publicly traded giant's strategic direction.

Henri Beaufour's career is defined by his generational stewardship and active governance role within Ipsen. He and his sister inherited the company's control after their father's death in 2000. Under their oversight, Ipsen successfully executed a strategic pivot to become a specialty care powerhouse, divesting its Consumer HealthCare (CHC) division in 2022 and focusing entirely on high-value, R&D-intensive therapeutic areas (Oncology, Rare Disease, and Neuroscience).

His commitment is to ensuring the company continues its history of internal and external innovation, completing major acquisitions of rare disease specialists like Albireo (for $952 million in 2023). In October 2025, he and his sister concluded a new agreement with their holding companies (Highrock, Beech Tree, MR BMH) to govern the exercise of their voting rights until December 31, 2028, a move that ensures long-term family stability and governance over the multi-billion euro company.

Henri Beaufour's social impact is structural, stemming from Ipsen's role in discovering and providing transformative medicines for complex and rare diseases globally. The company's R&D efforts provide a critical structural contribution to global healthcare and patient well-being. The Fondation Ipsen supports medical research and rare disease initiatives.

His structural contribution is tied to the long-term family commitment to the pharmaceutical sector, ensuring its continuous R&D and global development.

Henri Beaufour maintains the professional, composed style of a European executive. His attire is consistently formal and high-quality, favoring tailored suits. His aesthetic reflects stability and intellectual authority, befitting his position in the global pharmaceutical industry.

Residing in Paris, France, his luxury is the immense security and financial reward derived from his multi-billion euro fortune. His life is dedicated to the stewardship of his family's legacy and his commitment to biopharmaceutical innovation and strategic governance.